Showing results (31-40 of 73) with videos related to
Sort By:
Pageof 8
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2006
A phase I trial to determine the optimal biological dose of celecoxib when combined with erlotinib in advanced non-small cell lung cancerKaren L Reckamp, Kostyantyn Krysan, Jason D Morrow, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 26, 2012
Association between circulating tumor cells and prognosis in patients with stage III melanoma with sentinel lymph node metastasis in a phase III international multicenter trialSojun Hoshimoto, Tatsushi Shingai, Donald L Morton, et al.Neuro-Oncology Practice|August 7, 2019
Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survivalLaura Dovek, Nhung T Nguyen, Byram H Ozer, et al.Circulation|July 2, 2013
Cocaine-induced vasoconstriction in the human coronary microcirculation: new evidence from myocardial contrast echocardiographySwaminatha V Gurudevan, Michael D Nelson, Florian Rader, et al.The American Journal of Cardiology|April 13, 2020
Peripheral Blood Flow Changes to Cutaneous and Muscular Beds in Response to Acute Hookah SmokingMary Rezk-Hanna, Michael D Nelson, Florian Rader, et al.Circulation|December 29, 2018
Sustainability of Blood Pressure Reduction in Black BarbershopsRonald G Victor, Ciantel A Blyler, Ning Li, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 1, 2005
Serial monitoring of circulating melanoma cells during neoadjuvant biochemotherapy for stage III melanoma: outcome prediction in a multicenter trialKazuo Koyanagi, Steven J O'Day, Rene Gonzalez, et al.Arthritis Research & Therapy|January 1, 2017
Changes in plasma CXCL4 levels are associated with improvements in lung function in patients receiving immunosuppressive therapy for systemic sclerosis-related interstitial lung diseaseElizabeth R Volkmann, Donald P Tashkin, Michael D Roth, et al.Arthritis and Rheumatism|May 7, 2011
Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung diseaseMichael D Roth, Chi-Hong Tseng, Philip J Clements, et al.Arthritis & Rheumatology (Hoboken, N.J.)|April 5, 2017
Mycophenolate Mofetil Versus Placebo for Systemic Sclerosis-Related Interstitial Lung Disease: An Analysis of Scleroderma Lung Studies I and IIElizabeth R Volkmann, Donald P Tashkin, Ning Li, et al.Pageof 8